News Celgene scores at ASH18 with double luspatercept data A pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have set up a filing for the new drug in mid-2019.
News Spark reassures on safety of haemophilia gene therapy Study of nine patients produce encouraging results
News As rituximab biosimilars close in, Roche showcases Gazyva su... Roche faces competition against its blockbuster haematology drug
News CAR-Ts to take centre stage at ASH haematology congress Haematology is one of the most exciting areas in drug development today, with waves of new treatments emerging for hard-to-treat diseases.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.